CVC Capital Partners and other private equity owners are exploring options for generic drugmaker Alvogen, including a sale, which could be valued at about $4 billion, Bloomberg reported.
Alvogen’s controlling shareholders have held talks with Shanghai Pharmaceuticals Holding Co for the sale of Alvogen’s U.S. business, Bloomberg said, citing people familiar with the matter.
The drugmaker will keep its Asian and central European operations, Bloomberg reported.
According to the report, Alvogen’s owners may also have talks with other international buyers.
European private equity fund CVC and Singaporean sovereign wealth fund Temasek had bought a controlling stake in Alvogen in 2015.
Shanghai Pharmaceuticals was earlier planning to tie up with a consortium to make an offer for German generics drugmaker Stada Arzneimittel, which fell apart in May.
A CVC spokesman declined to comment. Alvogen was not immediately available for comment. Reuters was unable to immediately reach Shanghai Pharma for comment.
Latest posts by supriya kashyap (see all)
- Natco’s partner Alvogen gets nod for influenza drug in US - November 6, 2017
- USFDA moves to more efficient global pharmaceutical manufacturing inspections - November 6, 2017
- Sanofi refines expectations on drop in sales at diabetes arm - November 6, 2017